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1. Introduction
The pharmaceutical industry represents a capital 
intensive sector whose competitiveness is mostly 
based on technology, which is a characteristic for 
segments of the high-technology industry. Al-
though the pharmaceutical industry is based on 
production innovation and high level of R&D activ-
ity like other high-technology industries, there are 
certain evident particularities (Bezić and Galović, 
2013). In other words, the pharmaceutical industry 
invests, by far, the largest amount in research and 
development (R&D) (as a proportion of sales) of any 
industry. 
Generally speaking, the pharmaceutical industry is 
under the influence of two main factors: large phar-
maceutical companies and state legislation. State 
legislation covers the safety, effectiveness, and price 
of the pharmaceutical products, but it also devotes 
attention to the importance of R&D and innovative 
policy. The world’s supply of the pharmaceutical in-
dustry is characterized by a small number of indus-
trial economies on a high-technology and product 
innovation level (Karn, 1997). World demand for 
pharmaceutical products mostly records a growing 
trend. The demand can be determined by income 
level as well as price movements, distribution, age 
of the population, health care system, etc.  
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One of the main threats to the competitiveness of 
pharmaceutical companies, among other things, is 
reflected in the inability to maximize benefits from 
knowledge and innovation, in other words, the so-
called “technological spillovers”. Namely, if pharma-
ceutical companies produce innovation accepted 
by competitive companies without any costs, they 
can face the loss of their competitiveness (Bezić and 
Galović, 2013). 
Products of the pharmaceutical industry are con-
tinuously placed on the market with the objective 
to sustain and prolong human life. Taking into 
consideration that health is a basic human need, 
pharmaceutical products have a significant social 
impact in relation to other industries. Pharmaceuti-
cal products are chemical and biological substances 
used in therapies and prevention of illnesses. The 
pharmaceutical industry may be viewed from the 
aspect of consumers. Namely, the pharmaceutical 
industry comprises a group of companies which 
sell and distribute medicaments as final products. 
From the manufacturers’ point of view, the phar-
maceutical industry is defined in a narrower sense 
which implies manufacturing and processing activi-
ties (Reekie, 1975: 1). Multinational corporations 
and foreign direct investments are a driving force 
behind the world pharmaceutical manufacturing 
and trade. In general, pharmaceutical products 
have been classified by the distribution channels 
and choice of use into two main groups: over-the-
counter (OTC) and prescription (ethical) products. 
The first group (OTC) consists of drugs which have 
small market shares, but their importance is grow-
ing.  The second group (ethical) accounts for the 
bulk of medicines sold on prescription. In many 
countries, prescription drugs are available only 
through retail pharmacies or hospitals. Therefore, 
pharmacists and physicians are important parts of 
the distribution channel. Price competition is often 
more aggressive. Generic drugs are out-of-patent 
products which may be produced by more than 
one company because their patents have already 
expired. These types of drugs are price-competitive 
since they contain the same active ingredient as the 
original brand. Generic drugs may be substituted 
for the prescribed brand name if they are cheaper 
(Prasit, 1997).
In this paper several indicators of export and import 
of pharmaceuticals in the OECD countries are ana-
lyzed in order to measure international trade and 
competitiveness. 
Moreover, definitions of competitiveness by the 
OECD and DTI (Department of Trade and Industry) 
point out the significance of technological factors in 
the creation of competitiveness. DTI (DTI, 1994) 
defines competitiveness of firms as a possibility for 
manufacturing of adequate goods and services, at 
the right time and at the right price. The definition 
by the OECD (OECD, 1992), from the micro aspect, 
includes competitiveness which refers to a firms’ 
ability to compete, to maximize profit and realize 
growth based on costs and prices by using technol-
ogy, improvement of quality, and maximization of 
the effect of its products. Many scientists explore 
the relationship between competitiveness and tech-
nological possibilities. Scientists like Kaldor (1971), 
Porter (2001), Lall (2001), and Wignaraja (2003), 
and institutions like the OECD challenged in an ar-
gumented manner the opinions of other scientists 
who tried to define competitiveness only from the 
aspect of price-based factors with emphasis on non-
price factors such as technology. 
The discussion led to the revision of traditional 
theories in the framework of the problem of com-
petitiveness. There are two aspects which clarify the 
term “competitiveness” in more detail. The general 
macroeconomic aspect presents international com-
petitiveness in the framework of price-based fac-
tors. On the other hand, the microeconomic aspect 
tries to define competitiveness on the firm level with 
the factors which are not price-based and emphasis 
is placed on analysis of the rivalry between firms.
The macroeconomic aspect is accompanied by in-
ternal and external balance of economies where 
special attention was devoted to effects of price-
based factors on the competition. The microeco-
nomic aspect analyzed internal company dynamics 
which makes companies strong or weak in relation 
to influences (Wignaraja, 2003). 
The microeconomic aspect refers to presentation 
of competitiveness on the firm level. Perspective as 
such includes rivalry among firms and their strate-
gies. In the past few years, the microeconomic as-
pect implies new dimensions: the impact of tech-
nology and innovation. Lall (2001) criticizes the 
neoclassical theory, whose hypotheses are based 
on the thesis that technology is available to all firms 
which are able to use technology at technically 
“high” levels. However, this long learning process 
starts by import of technology followed by innova-
tion. 
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Most experts are partly or completely familiar 
with two theoretical frameworks from trade based 
on comparative advantages: Ricardo’s theory and 
Heckscher-Ohlin (H-O) theory. Ricardo’s theory 
covers comparative advantages achieved on the ba-
sis of different technologies, while the H-O theory 
uses as an example the equal level of technology 
in all countries. The H-O theory at the same time 
points out the significance of comparative advan-
tages in relation to different levels of costs derived 
from unequal prices of the manufacturing factors 
in the analyzed countries. Postulates of traditional 
trade theories are based on the principle of relative 
prices of comparative advantages, i.e. inequalities in 
prices which are under the influence of supply and 
demand factors (Bezić and Galović, 2013).
According to the H-O theory, a comparative advan-
tage of an economy is defined by the relative scarcity 
factor. However, irregularities in measuring of com-
parative advantages and verifying of the Heckscher-
Ohlin theory were discovered by empirical analysis 
because of the inability to observe relative prices 
under the influence of autarky (Balassa, 1989: 42). 
Bearing in mind these insights, Balassa (1965) sug-
gested avoiding full inclusion of all the components 
which affect the comparative advantages of differ-
ent economies. Instead, it is pointed out in Balassa’s 
analysis that “revealed” comparative advantage is in 
accordance with the theoretical postulates, except 
for one exception, which is the inability to analyse 
relative prices. Deriving conclusions from the ana-
lyzed data, Balassa called the results of his research 
revealed comparative advantage, i.e. RCA (Revealed 
Comparative Advantage). RCA is, at the same time, 
an accepted method in the analysis of trade in the 
observed countries. Furthermore, Balassa created 
an index (known as Balassa’s Revealed Comparative 
Advantage Index) whose main objective is measur-
ing comparative advantages of countries. It should 
be pointed out that Balassa’s index is reflected in the 
identification of revealed comparative advantages 
instead of revealing “hidden” elements of econom-
ic advantages of an economy (Bezić and Galović, 
2013). 
However, the initial version of Balassa’s Revealed 
Comparative Advantage Index was modified and 
revised, so that, presently, there are different indi-
ces for measuring comparative advantages. In some 
research, the RCA is measured on the global level 
(Vollrath, 1991), while in other studies, the RCA is 
measured on the regional level. There are also cases 
in which Balassa’s Revealed Comparative Advan-
tage Index was used as a measure for bilateral trade 
(Dimelis and Gatsios, 1995).
According to Krugman (1985), trade models have 
given a precise description of the pattern of trade 
in goods. In traditional theory, the answer emerges 
from the explanation of trade itself: countries pro-
duce goods that would have been relatively cheap 
in the absence of trade. The comparative advantage 
may arise from a variety of sources, but in any case 
the attributes of a country determine what it pro-
duces. Krugman (1996) claims that traditional the-
ory is the usual basis for advocating free trade, one 
of the most strongly held positions in the econom-
ics profession (although actually even in traditional 
theory a second-best case can be made for protec-
tion as a corrective for domestic market failures). 
The new trade theory suggests a more complex 
view. The potential gains from trade are even larger 
in a world of increasing returns, and thus, in a way, 
the case for free trade is all the stronger. New trade 
models show that it is possible (not certain) that 
such tools as export subsidies, temporary tariffs, 
and so on, may shift world specialization in a way 
favourable to the protecting nation. 
The basic scientific hypothesis of the paper is set up, 
namely, that it is possible to estimate the interna-
tional competitiveness of the pharmaceutical indus-
try within 21 OECD countries (including several EU 
Member Countries) by using various international 
trade and competitiveness indicators.
In this relation, the basic objective of the research 
is to measure international competitiveness, ob-
jectively estimate international trade of the phar-
maceuticals of 21 OECD countries, and to propose 
measures and activities for the improvement of their 
international trade competitiveness in accordance 
with the results. 
The paper consists of five systematically interrelated 
parts. After the Introduction, the second part of the 
paper presents the research methodology. The third 
part includes the analytical framework and results 
of international competitiveness based on the anal-
ysis of foreign trade activity and export competi-
tiveness of the OECD pharmaceutical industry. The 
final part comprises proposals, recommendations 
and conclusions. 
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2. Methodology
The analytical aspect is based on scientific results of 
several indicators that show the level of internation-
al competitiveness of the pharmaceutical industry 
which includes 21 OECD countries. Implemented 
indicators have been frequently used in contempo-
rary economic research, which evaluates the econ-
omy’s structural strengths and weaknesses via the 
composition of international trade flows (Bezić and 
Galović, 2013). In other words, these indicators ad-
dress the question of trade specialization and per-
formance in international markets. The purpose of 
the methodology used in this study also implies the 
importance of the foreign market for pharmaceuti-
cals in a country and what degree of domestic de-
mand is satisfied by imports. Furthermore, the most 
commonly used indicators, indices, and ratios are 
implemented to assess trade patterns and charac-
teristics, and changes in them. Besides elementary 
and well-known indicators, this research uses basic 
indicators that are suggested by the OECD Statisti-
cal Database (2014) and World Bank (2014). These 
indicators were used in previous studies (Bezić and 
Galović, 2013; Bezić and Galović, 2013; Kandžija et 
al., 2014, Bezić and Galović, 2014) of other manu-
facturing sectors which have provided objective re-
sults of international trade and international com-
petitiveness.
Some analyses of factors influencing the success or 
failure of efforts to promote industrialization and 
growth conclude that a growing level of intraindus-
try trade (plays an important positive role (World 
Bank, 2014). Intraindustry exchange produces extra 
gains from international trade over and above those 
associated with comparative advantage because it 
allows a country to take advantage of larger mar-
kets.
Intra-industry trade (IITR) represents the value of 
total trade remaining after subtraction of the abso-
lute value of net exports or imports of pharmaceuti-
cals. For comparison between countries and indus-
tries, the measures are expressed as a percentage 
of each industry’s combined exports and imports. 
Intra-industry trade represents one of the key em-
pirical reasons for emphasizing the role of increas-
ing returns and imperfect competition in the world 
economy. According to the OECD Statistical Data-
base (2014), intra-industry trade of pharmaceuticals 
is calculated as follows:
(1)
wherein:
expoi - export activity of sector “i”
impoi -  import activity of sector “i”
This index varies between 0 and 100. If a country 
exports and imports roughly equal quantities of a 
certain product, the index value is high. Whereas if 
trade is mainly one-way (whether exporting or im-
porting), the index value is low.
The “contribution to the trade balance” or “CMTB” 
makes it possible to identify an economy’s structural 
strengths and weaknesses via the composition of in-
ternational trade flows (OECD Statistical Database, 
2013). It takes into account not only exports, but 
also imports, and tries to eliminate business cycle 
variations by comparing an industry’s trade balance 
with the overall trade balance. It can be interpreted 
as an indicator of “revealed comparative advantage” 
(Balassa, 1965: 93; Balassa, 1978: 203) as it indi-
cates whether an industry performs relatively better 
or worse than the manufacturing total, no matter 
whether the manufacturing total itself is in deficit 
or surplus. The “contribution to the manufacturing 
trade balance” is the difference between the actual 
and this theoretical balance:
(2)
wherein:
expoi - export activity of sector “i”
impoi -  import activity of sector “i”
expomanuf - export activity of total manufacturing 
sectors
impomanuf -  import activity of total manufacturing 
sectors
A positive value for an industry indicates a struc-
tural surplus and a negative one a structural deficit. 
The indicator is additive and individual industries 
can be grouped together by summing their respec-
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tive values: by construction, the sum over all in-
dustries is zero. The next indicator called “Export 
import ratio” shows exports as a percentage of im-
ports. The EXIM ratio can be calculated as follows: 
(3)
wherein:
expoi - export activity of sector “i”
impoi -  import activity of sector “i”
Another simple indicator is used within this paper. 
Hence, this indicator (TBAL) is calculated in real 
numbers of national currencies and highlights the 
trade pattern of each industry. It can be seen in the 
following formula:
(4)
Trade balance is one of the macroeconomic indica-
tors which are used to gauge the competitiveness of 
a sector at the national level. When exports exceed 
imports, the balance is in surplus, and when im-
ports exceed exports, the balance is in deficit.
Furthermore, composition of manufacturing ex-
ports of goods indicator (XSHM) shows the exports 
in a given manufacturing industry (in this case the 
OECD pharmaceutical industry) as a percentage of 
total manufacturing exports. The XSHM indicator 
is calculated as follows:
(5)
wherein:
expoi - export activity of sector “i”
expomanuf - export activity of total manufacturing 
sectors
Finally, the import penetration (MPEN) indicator 
can be calculated as a ratio of imports to the sector’s 
production adjusted for the foreign trade balance 
(difference between exports and imports) according 
to the following formula:
(6)
For a given country, a value close to 100 in a certain 
industry, implies that domestic demand is mainly 
fulfilled by imports and domestic production tends 
to be exported (the OECD Statistical Database, 
2013). A value close to 0 means self-sufficient, i.e. 
domestic demand is mainly satisfied by domestic 
production. A value above 100 illustrates measure-
ment problems that may occur when combining 
production and trade data. It is important to bear in 
mind that exports can exceed production. 
3. Results
In the analysis of the outlined problem, the starting 
point is to identify the international competitive-
ness of the pharmaceutical industry of 21 OECD 
countries in the period between 2004 and 2009. 
One of the main reasons of choosing this period 
and number of observed countries lies in the lim-
ited availability of data and observations for a spe-
cific subsector (in this case pharmaceuticals – code 
C2423) which were found in the OECD Statistical 
Database (2014). Observed countries are classified 
as a group of developed economies according to the 
UN Classification (United Nations, 2013) prepared 
by the Development Policy and Analysis Division 
(DPAD) of the Department of Economic and So-
cial Affairs of the United Nations Secretariat (UN/
DESA).  In order to analyze pharmaceuticals, it is 
important to consider ongoing trade within exam-
ined countries. Several indicators, which are based 
on export and import, can be used to measure the 
performance and competitiveness of a certain sec-
tor for each country. 
In a given year, the values of an indicator can dif-
fer between countries, which allow an international 
comparison. The value of an indicator may also 
differ between different years, within a different 
country.  In this particular study, six indicators will 
be calculated for the 21 OECD member countries: 
IITR, CMTB, EXIM, TBAL, XSHM and MPEN. The 
data is extracted from the OECD Statistical Data-
base. Values can be found within Appendix I.
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Source: OEcd database, 2014
The trade balance is the difference between exports 
and imports in the specified sector. This indicator 
shows the competitiveness of a certain sector at the 
national level. It is shown in real number and in na-
tional currencies, so when comparing the countries 
the size of the company is important. The larger the 
economy, the higher the trade balance will be. Ob-
vious positive scores are found in Germany, Ireland 
and the UK. Ireland creates a great surplus on the 
trade balance of pharmaceuticals. One of the rea-
sons are Ireland’s intellectual property laws which 
provide companies with generous incentives to in-
novate, the Irish tax system that offers huge sup-
port to turn brilliant ideas into the finished prod-
uct, a highly competitive corporate tax rate, which 
is a major incentive, and no tax is paid on earnings 
from intellectual property where the underlying 
R&D work was carried out in Ireland. Furthermore, 
pharmaceuticals are a major contributor to the Irish 
economy. Ireland is the No. 1 European location for 
international pharmaceutical investment as well. 9 
out of the top 10 pharmaceutical companies are lo-
cated in Ireland, 7 out of 10 pharmaceutical block-
busters are produced in Ireland, which is home to 
over 100 companies engaged in pharmaceutical and 
chemical related activities. 
Because of its highly advanced incorporation of the 
latest technology and the strict quality control pro-
cedures, this country creates a wide range of prod-
ucts and services. Hereby it is not only the largest 
net exporter of pharmaceuticals in Europe, but in 
the whole world as well. Germany also shows rising 
figures, mainly because of the great competitive-
ness of the country. The chemical and pharmaceu-
tical industry is Germany’s third-largest industrial 
sector in terms of revenues. It is characterized by 
an extensive and comprehensive infrastructure that 
integrates state-of-the-art transportation networks 
with high-quality communication and energy infra-
structure. Pharmaceutical companies in Germany 
benefit from the close proximity of leading machine 
and equipment manufacturers. This guarantees 
continuous production and short downtimes.  Lux-
embourg notes the biggest deficit. Being one of the 
smallest countries in Europe and being orientated 
towards the service and financial sector this country 
imports far more pharmaceuticals than it imports. 
The biggest deficits of the OECD pharmaceuti-
cal industry were recorded in Spain, Luxembourg, 
Greece and the Czech Republic.  Furthermore, the 
final results of the export import ratio are presented 
in Figure 2.
Figure 1 Trade balance (TBAL) indicator from 2004 to 2009
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Source: OEcd database, 2014
The export-import ratio identifies the exports as a 
percentage of imports. A percentage higher than 
one hundred means that exports are higher than 
imports and will consequently create a surplus on 
the national trade balance. 
Figure 3 Intra-industry trade indicator (IITR) 
from 2004 to 2009
Source: OEcd database, 2014 
In this figure the exports as a percentage of imports 
in the pharmaceutical industry are shown. It must 
be noticed that Denmark, Slovenia and Sweden ob-
tain generally higher scores but the most remark-
able is Ireland. Ireland is a market leader in the 
pharmaceutical industry, with over 120 overseas 
companies having their plants there including 9 
of the 10 largest pharmaceutical companies in the 
world. This explains the rising export import ratio 
of 718% implying that Ireland exports seven times 
more pharmaceuticals than it imports. This indica-
tor also shows the worst performers which include 
Figure 2 Export import ratio indicator from 2004 to 2009 (EXIM)
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Poland, Greece, Estonia, the Czech Republic and 
the Slovak Republic. In addition, Figure 3 shows the 
intra-industry trade of the pharmaceutical industry 
of 21 OECD countries in the period between 2004 
and 2009.
This indicator shows the value of total trade remain-
ing after subtraction of the absolute value of net ex-
ports or imports of pharmaceuticals in Europe. In 
this figure, high scores are obtained by some well-
developed and industrialized EU countries. In 2009, 
Austria gets a score of 95% followed by Belgium 
with 91%. France, Germany, Hungary, Italy and the 
Netherlands all vary in score between 86% and 96%. 
High percentages imply that these entities export 
and import roughly equal quantities of pharmaceu-
ticals, whereas lower scores imply a one-way trade 
(import or export). Lower percentages are found 
in countries such as Estonia, Ireland, Luxembourg 
and Poland, varying in scores between 24% and 35% 
which could indicate the possible existence of one-
way trade or a lower level of trade. This means that 
the export and import in these countries form a sig-
nificant part of the total traded goods. 
Figure 4 Composition of manufacturing exports 
of goods indicator from 2004 to 2009 (XSHM)
Source: OEcd database, 2014 
The logic of this outcome becomes clear as Belgium 
and the Netherlands are smaller countries and thus 
have an entire export- and import-based economy 
with a much more diversified product portfolio. 
Germany is one of the most powerful economies of 
the EU, which produces and trades a lot of differ-
ent goods across Europe. Portugal and Ireland on 
the other hand score lower, implying that the share 
of pharmaceuticals to the total amount of traded 
goods is more significant. Figure 4 represents the 
composition of manufacturing exports of pharma-
ceuticals of 21 OECD countries in the period be-
tween 2004 and 2009.
This indicator shows the proportion of export for a 
specific sector compared to the total export of the 
manufacturing sector. This will thus identify how 
important this sector is in the outflow of manufac-
tured products to other countries. In this figure the 
share of the pharmaceutical industry in comparison 
to the total manufacturing exports are revealed by 
the composition of manufacturing exports of goods. 
Ireland achieves an increasing percentage of phar-
maceutical -goods compared to all exported goods, 
reaching 30% of the total. It has to be pointed out 
that the pharmaceutical industry in Ireland is high-
ly advanced. It incorporates the latest technology, 
state of the art equipment and strict quality control 
procedures. 
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Ireland’s pharmaceutical industry consists of a wide 
range of products and services, from research and 
development for new medicines to the manufactur-
ing and marketing of new medicines for humans and 
animals. An important aspect in the development of 
the sector, which has helped to significantly boost 
its contribution to the Irish economy, has been the 
success of the sector in diversifying the nature of its 
investment in Ireland from the original bulk active 
plants to higher value activities. The maintenance of 
a culture of support for innovation is significant to 
the success of such a move up the value chain. The 
other major impacts come from the fiscal environ-
ment of Ireland. Belgium is the second best coun-
try in this chart with an approximate gap of 15% 
between first and second place, however pharma-
ceuticals are taking an increasing part of the total 
exports. Moreover, the final results of import pen-
etration indicator are presented in Figure 5. 
Import penetration shows how dependant domestic 
demand in a certain sector is relying on foreign pro-
ducers rather than on domestic production. 
Figure 5 Import penetration of the OECD phar-
maceutical industry from 2004 to 2009 (MPEN)
Source: OEcd database, 2014 
It is defined as the ratio between the values of im-
ports as a percentage to domestic demand for this 
specific sector. Smaller countries usually have 
higher ratios as they have smaller economies and 
will rely more heavily on foreign producers.  The 
ratio of imports to the sector’s production adjusted 
to the foreign trade balance gives more insight in 
the import penetration. In other words, this is the 
percentage of total demand for pharmaceuticals 
that is covered by import. Belgium stands out in 
this graph, as it is a small country living from the 
import and export, especially of pharmaceuticals. 
Due to very high figures in export, this rate exceeds 
the 100% mark. Italy, Finland and Germany achieve 
the lowest scores, which implies that these coun-
tries are most self-sufficient. Finally, the results of 
the contribution to the trade balance are presented 
within Figure 6. 
The contribution to the trade balance identifies the 
competitive advantage of a country in the specified 
sector. As it is compared to the total manufactur-
ing in this country, the indicator will then show how 
important the specific sector is for the country. The 
higher the value of this indicator the more impor-
tant this sector is for the manufacturing sector as 
a whole. 
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Source: OEcd database, 2014
The composition of international trade flows 
makes it easier to visualize an economy’s structural 
strengths and weaknesses. The contribution to the 
trade balance compares the pharmaceutical indus-
try’s trade balance with the overall trade balance. 
First of all, in this graph a few remarkably high re-
sults are visible in Denmark, Ireland, Slovenia, Swe-
den and UK with a positive score between 1.7% and 
9.4%. This makes sense because the previous graph-
ic indicated that pharmaceuticals are a significant 
part of the total export of these countries. 
There are, on the other hand, many countries ob-
taining an extremely low sore such as the Czech 
Republic, Estonia, Finland and Luxembourg. These 
countries import more pharmaceuticals then they 
export and thus create a negative effect on the total 
trade balance. Finally, yet importantly, there are a 
few countries such as Austria, Belgium, France and 
Spain which recorded results around the zero mark. 
The indicator of revealed comparative advantage 
shows whether the pharmaceutical industry per-
forms relatively better or worse than the manufac-
turing total (independent of whether this total is in 
deficit or surplus). Projecting this on the obtained 
results, high scores are translated in structural sur-
pluses and negative on structural deficits. 
4. Conclusion
Aggregation of the results of the calculated indices 
leads to a series of interesting insights related to 
international competitiveness of the OECD phar-
maceutical industry. When it comes to the OECD 
intra-industry trade of pharmaceuticals, older Eu-
ropean member states got higher scores. The logic 
of this outcome becomes clear as Belgium and the 
Netherlands are smaller countries and thus have an 
entire export- and import-based economy with a 
much more diversified product portfolio. Germany 
is one of the most powerful economies of the EU, 
which produces and trades many different goods 
across Europe. Portugal and Ireland on the other 
hand score lower, implying that the share of phar-
maceuticals to the total amount of traded goods is 
more significant.
The composition of international trade flows 
makes it easier to visualize an economy’s structural 
strengths and weaknesses. Remarkably high results 
are visible in Denmark, Ireland, Slovenia, Sweden 
and the UK. This makes sense because the results 
of several indicators indicated that pharmaceuti-
cals are a significant part of the total export of these 
countries. As a market leader in the pharmaceutical 
industry, Ireland includes 9 of the 10 largest phar-
maceutical companies in the world. This explains 
Figure 6 Contribution to the trade balance indicator from 2004 to 2009 (CMTB)
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the highest export-import ratio of 718% implying 
that Ireland exports seven times more pharmaceu-
ticals than it imports. It has to be pointed out that 
most of the above-mentioned countries are charac-
terized by above-average share of R&D activity and 
innovation, which enables faster adjustment to new 
conditions on the international market and an in-
crease in international competitiveness.
Ireland also creates a great surplus on the trade bal-
ance of pharmaceuticals. Because of its highly ad-
vanced incorporation of the latest technology and 
the strict quality control procedures, this country 
creates a wide range of products and services. Ger-
many as well shows rising figures, mainly because 
of the great competitiveness of the country. Luxem-
bourg has recorded the biggest deficit. Being one 
of the smallest countries in the EU, this country 
imports far more pharmaceuticals than it exports. 
Ireland achieves an increasing percentage of phar-
maceutical goods compared to all exported goods, 
reaching 30% of the total. In terms of the trade bal-
ance indicator, Belgium is the second best country 
with an approximate gap of 15%. However, pharma-
ceuticals are taking an increasing role of the total 
export’s activity. Overall, the leading position of Ire-
land as a global market player is shown in all indica-
tors. The main reason for this is the establishment 
of the most important players in the pharmaceutical 
sector in that country. Furthermore, the majority of 
the implemented indicators also pointed to the vi-
tal role Germany and France as powerful European 
and OECD countries. Finally, yet importantly, the 
smaller member states show differences in export- 
and import-figures. States such as Belgium and the 
Netherlands live from import and export, which 
becomes visible in the analysis of the pharmaceuti-
cal sector. On the other hand, countries like Luxem-
bourg have lower percentages concerning pharma-
ceuticals, as they do not imply a great part of total 
industry in that country.
Generally, the conclusion is derived that most 
highly developed countries with their propulsive 
pharmaceutical sectors have preconditions for im-
provement of international competitiveness and 
development of revealed comparative advantages, 
while other countries have smaller possibilities for 
reaching this scenario. Concerning the results, the 
basic hypothesis is confirmed. In other words, the 
level of international trade and competitiveness of 
the pharmaceutical industry within 21 OECD coun-
tries (including several EU Member Countries) is 
shown. Hereby, the main objective and purpose of 
this research are validated.  
Consequently, in order to improve international 
competitiveness and comparative advantages of 
firms, the branch of medical and pharmaceutical 
products should invest in:  
• creating business strategies which increase the 
market share after the introduction of generic 
medicines,
• marketing and other promotional activities,
• R&D activities and innovation activities, and 
continuous engagement and training of re-
searchers and R&D staff in firms.
• raising the firms’ awareness of growing markets 
and expansion to growing markets,
• more detailed identification of activities of the 
growing competition, especially from Asian 
countries,
• revision and conversion of the export expansion 
programme,
• establishing of stronger partnerships with large 
clients,
• openness to “joint venture” i.e. common invest-
ments in order to supply new technology.
Besides those propositions, the observed countries 
should provide an adequate and company-friendly 
fiscal environment in order to achieve a higher level 
of competitiveness. Application of the results of 
this research may contribute to the improvement of 
international competitiveness in the OECD phar-
maceutical industry, but this implies undertaking 
measures within the pharmaceutical firms. There-
fore, in order to overcome the problems of interna-
tional competitiveness, a comprehensive approach 
is necessary on the level of macro-environment 
and on the level of micro-environment. In other 
words, firms should ensure all the necessary pre-
conditions for adjustment to a competitive environ-
ment. Adoption of the above-mentioned measures 
would provide the OECD pharmaceutical industry 
with a greater possibility to take and keep a com-
petitive position on the market. Adequate transfer 
of knowledge and technology may, of course, result 
in growth of export activity of the pharmaceutical 
firms in the OECD. Opening room for investments 
also plays a significant role in the stimulation of ex-
port expansion of pharmaceutical firms.
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Appendix I. The detailed results of included indicators for 21 OECD pharmaceuticals from 2004 till 
2009
Industry C2423 Pharmaceuticals
Time 2004 2005 2006 2007 2008 2009
Variable Country
Intra-industry 
trade
Austria 96,332413 97,891587 96,135589 96,163133 93,737946 94,836733
Belgium 98,731271 99,093075 95,708512 93,343513 93,497901 91,493544
Czech Republic 43,840516 49,021207 56,068877 55,229044 54,114993 54,592337
Denmark 56,801376 54,69424 57,705537 57,528698 59,893096 60,88576
Estonia 30,964052 27,668888 24,830374 26,052788 26,226789 24,949941
Finland 59,935994 64,620522 67,340924 64,634528 67,133336 72,271478
France 91,373408 90,091383 88,815406 89,90317 88,433875 92,593369
Germany 87,492617 89,556185 88,42365 87,880071 83,654374 86,178373
Greece 45,34683 49,812018 45,495801 42,494785 37,065878 36,906089
Hungary 87,156539 92,576501 94,11188 99,589304 98,301952 97,131534
Ireland 23,578479 24,90645 30,689244 30,023706 30,175557 24,443152
Italy 92,071229 96,049321 93,733356 90,777906 89,716083 86,096415
Luxembourg 28,245361 27,046128 28,640471 32,092271 34,826136 33,027388
Netherlands 97,687787 98,291193 98,582342 98,062261 98,39685 95,978668
Poland 25,679919 31,473032 34,470826 38,808856 41,043749 ..
Portugal 32,930086 32,219881 31,848216 .. .. ..
Slovak Republic 36,157942 43,207791 39,457484 33,106683 35,52927 ..
Slovenia 66,079077 69,9613 62,373673 61,479797 60,321347 63,008001
Spain 70,359497 81,024032 83,785583 86,541423 83,615784 78,478495
Sweden 52,009968 55,679726 54,137112 59,141154 63,161405 62,764432
United Kingdom 87,618965 87,059332 84,25828 86,358402 80,259844 ..
Contribution to 
manufacturing 
trade balance
Austria -0,2322723 -0,0445316 -0,0199465 0,0105917 0,1412318 0,257773
Belgium -1,0053981 -0,8897019 -0,2398772 0,1424674 0,1567182 0,4654558
Czech Republic -1,1254839 -1,080932 -0,865182 -0,9037473 -1,0101975 -1,3673808
Denmark 2,5591065 2,821932 2,5426936 2,5052254 2,3651546 2,6623976
Estonia -0,795995 -0,7440493 -0,6335228 -0,7124736 -0,9058308 -1,3591204
Finland -1,4063437 -1,2328366 -1,2364241 -1,055522 -1,1070553 -1,355168
France 0,420156 0,5670528 0,6138547 0,7000527 0,8387718 0,8936619
Germany -0,2940933 -0,3592537 -0,2618166 -0,360714 -0,1432429 -0,1367789
Greece 0,0495501 0,0072663 -0,3955968 -0,452799 -0,7326636 -0,8211778
Hungary -0,2897914 -0,233209 -0,2377204 -0,0627967 -0,1917351 -0,1730119
Ireland 7,8291417 7,1882269 6,53515 6,7855706 7,7338923 9,3464578
Italy -0,6198078 -0,4984774 -0,5656408 -0,7101634 -0,8570462 -1,3062802
Luxembourg -0,7973062 -0,8171161 -0,7566005 -0,7618185 -0,7556456 -1,027607
Netherlands -0,2572794 -0,3494683 -0,3471602 -0,3923161 -0,4539914 -0,4470973
Poland -1,6093499 -1,5540985 -1,4606183 -1,2876828 -1,415548 ..
Portugal -1,5564948 -1,4757322 -1,6028704 .. .. ..
Slovak Republic -1,3416036 -1,2432833 -1,1000549 -1,2524576 -1,1529711 ..
Slovenia 1,8520279 1,6153854 2,0698708 2,1823799 2,5100071 2,7133828
Spain -0,5835452 -0,1404999 -0,000794 0,1407937 -0,1445892 -0,9068881
Sweden 1,6941162 1,4455599 1,7228068 1,4492543 1,24835 1,7015988
United Kingdom 1,5814102 1,5672127 1,8027248 1,9688954 2,2038529 ..
Export import 
ratio
Austria 92,924332 104,30765 108,0395 107,97991 113,36077 110,88875
Belgium 97,494332 98,202452 108,96783 114,26235 113,90854 118,59466
Czech Republic 28,074194 32,468936 38,955353 38,149257 37,09428 37,544333
Denmark 252,10415 265,66922 246,58719 247,65257 233,9283 228,48403
Estonia 18,318028 16,055654 14,175045 14,977411 15,092539 14,253032
Finland 42,791861 47,732879 50,762395 47,748165 50,526847 56,582099
France 118,88206 121,99681 125,18616 122,46157 126,15768 115,99819
Germany 128,59072 123,32349 126,18383 127,58288 139,07895 132,07679
Greece 29,32163 33,166447 29,44632 26,979923 22,748996 22,628735
Hungary 77,236677 86,179003 88,878601 100,82478 96,660608 105,90635
Ireland 748,23113 703,00485 551,69413 566,14029 562,7881 718,22508
Italy 85,3074 92,398936 88,205811 83,113134 81,350106 75,587098
Luxembourg 16,445181 15,637769 16,713673 19,11304 21,084532 19,780123
Netherlands 104,73388 103,47703 102,87609 103,95206 103,25854 108,37964
Poland 14,731475 18,675368 20,824623 24,076295 25,820783 ..
Portugal 19,710363 19,203635 18,94016 .. .. ..
Slovak Republic 22,068779 27,557359 24,577592 19,837034 21,602184 ..
Slovenia 202,66767 185,87233 220,64811 225,31012 231,55758 217,42001
Spain 54,272774 68,101174 72,095687 76,275787 71,844608 64,579923
Sweden 284,54167 259,19717 269,43234 238,17399 216,64907 218,65181
United Kingdom 128,26109 129,72839 137,3654 131,59298 149,19062 ..
Trade balance
Austria -271,73536 187,29508 408,03489 468,31762 863,3299 764,46069
Belgium -852,03035 -680,9595 3314,2865 6267,7875 6496,763 ..
Czech Republic -1374,7979 -1432,4225 -1374,5271 -1850,7123 -2392,5141 ..
Denmark 3394,5853 4022,3864 3907,0876 4320,665 4610,5016 ..
Estonia -9,4226667 -10,41075 -11,907 -15,205524 -19,604399 ..
Finland -955,25823 -963,87556 -1043,3112 -1093,4107 -1265,3268 -993,93229
France 3461,1484 4282,4948 5171,6719 5422,1209 7173,5029 4833,3459
Germany 7846,1399 7636,925 9745,01 12455,82 19686,165 ..
Greece -2046,6393 -2382,3543 -2737,1946 -3482,3163 -4333,1659 ..
Hungary -365,398 -249,456 -246,468 21,093 -118,488 ..
Ireland 18910,724 18034,104 15910,144 18592,239 23426,441 ..
Italy -2060,6667 -1144,1652 -1993,0105 -3363,3286 -4063,9084 -5544,5844
Luxembourg -252,88894 -272,13712 -273,47506 -316,41228 -367,68698 ..
Netherlands 501,28971 407,92917 398,41822 713,63938 831,75762 ..
Poland -2610,4024 -2758,1546 -3178,6425 -3725,848 -5157,5773 ..
Portugal -1651,4289 -1708,4839 -1942,2356 .. .. ..
Slovak Republic -655,08877 -711,20712 -815,92784 -1307,3758 -1414,4358 ..
Slovenia 541,45011 530,01058 799,66479 1066,7578 1308,8113 ..
Spain -4382,2976 -3309,4916 -3070,0965 -3186,2705 -4642,9891 ..
Sweden 4696,8288 4437,0885 5505,7784 5089,4979 4971,6277 ..
United Kingdom 5166,9091 5405,1535 7346,9234 7401,3148 10949,43 ..
Composition of 
manufacturing 
exports of goods
Austria 3,3602985 4,0611058 4,3500914 4,2589687 4,4959659 6,3203286
Belgium 11,890738 12,3607 12,088439 12,871015 12,402626 16,324377
Czech Republic 0,8487294 0,9220194 0,9647549 0,9854232 1,0339446 1,3621462
Denmark 8,7651013 9,1373737 8,4579723 8,2456379 8,1416989 10,053718
Estonia 0,5670414 0,4316542 0,344325 0,4056118 0,4539459 0,495726
Finland 1,2031303 1,377723 1,43141 1,1394164 1,3716263 2,1321065
France 5,6069574 5,8306581 5,7247107 5,9439442 6,3664269 8,2111309
Germany 4,1847066 4,3117746 4,3949992 4,6872605 5,1704257 6,3327019
Greece 6,5271921 7,9427664 6,4611993 6,3290818 5,8396033 7,7532019
Hungary 2,3234544 2,6002465 2,7596097 2,8678822 3,3624976 4,3214155
Ireland 22,201398 20,134074 18,872872 19,475337 23,49595 30,105889
Italy 3,503831 3,8658226 3,7013098 3,470842 3,4613307 4,4781054
Luxembourg 0,4305985 0,4163386 0,4067767 0,4850034 0,5839305 0,7652098
Netherlands 4,3280992 4,246244 4,3488661 4,7482332 5,9382847 8,2831096
Poland 0,6475239 0,7638996 0,8101326 0,8995384 1,1056484 ..
Portugal 1,1734024 1,1386412 1,1232905 .. .. ..
Slovak Republic 0,6971882 0,8855558 0,6596338 0,5834908 0,5830177 ..
Slovenia 6,9227407 6,6352015 7,2894653 7,4957014 8,1899714 9,831477
Spain 3,1301537 4,0063759 4,0417508 4,415705 4,6715543 5,6939694
Sweden 6,3739892 5,8701954 6,5203746 5,7242003 5,5842459 7,5410643
United Kingdom 7,6410784 7,4227127 7,8885386 8,5106994 8,8503199 ..
Import pene-
tration
Austria 130,41857 149,31524 176,59609 159,57167 .. ..
Belgium 312,27321 339,13296 449,94391 601,32819 .. ..
Czech Republic 82,456038 81,305613 84,231725 91,031041 .. ..
Denmark 88,582863 80,889904 83,088777 87,628105 .. ..
Estonia .. .. .. .. .. ..
Finland 97,034344 104,51986 106,85902 99,520579 .. ..
France 44,603422 47,389148 48,155658 51,199115 54,25987 ..
Germany 95,771697 99,623784 108,90869 106,6316 .. ..
Greece 91,277748 99,559991 97,52258 96,588739 .. ..
Hungary 64,579693 70,484082 77,601123 89,992041 .. ..
Ireland -24,791718 -28,01127 -43,893388 -91,544217 .. ..
Italy 48,40405 57,395532 56,098006 55,848434 .. ..
Luxembourg .. .. .. .. .. ..
Netherlands 118,1272 188,05371 213,47399 247,45511 .. ..
Poland 64,30995 63,524783 65,661744 67,823274 .. ..
Portugal 70,170043 68,646244 71,272406 .. .. ..
Slovak Republic 93,804241 98,969796 97,801917 97,744132 .. ..
Slovenia 71,972969 85,21837 98,250006 .. .. ..
Spain 54,230354 62,2493 63,403033 67,320046 .. ..
Sweden 52,717373 52,32 59,232236 60,046639 .. ..
United Kingdom 92,102384 84,336676 90,148518 97,20358 .. ..
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Tomislav Galović 
Međunarodna konkurentost farmaceutske 
industrije 21 OECd zemlje
Sažetak
Rad uključuje rezultate farmaceutske industrije 21 zemlje OECD-a u razdoblju od 2004. do 2009. godine. 
Temeljni je cilj istraživanja izmjeriti međunarodnu trgovinu i konkurentnost farmaceutske industrije zem-
alja OECD-a. Metodologija rada zasniva se na primjeni različitih pokazatelja koji uključuju intraindustri-
jsku trgovinu, trgovinsku bilancu, penetracije uvoza, udjela u industrijskom izvozu i ostalih važnih poka-
zatelja. Glavni rezultati istraživanja uključuju činjenice koje proizlaze iz mjerenja međunarodne trgovine i 
konkurentnosti te daju procjenu položaja farmaceutske industrije analiziranih OECD zemalja osobito na 
vanjskom tržištu, kao i preporuke i prijedloge radi dosega više razine međunarodne konkurentnosti.
Ključne riječi: međunarodna konkurentnost, međunarodna trgovina, zemlje OECD-a, farmaceutska in-
dustrija
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